Parkinson’s disease: 23andMe and Genentech to analyze 3,000 Parkinsons genomes

0
949

Privately held 23andMe Inc and Genentech are going to work together to generate whole genome sequencing data for about 3,000 people with Parkinson’s disease, in order to identify new therapeutic targets for treating the degenerative neurological condition. 23andMe, co-founded by Anne Wojcicki, the wife of Google co-founder Sergey Brin, will contribute the genome sequencing and data from its Parkinson’s disease community. Genentech, a unit of Roche Holding AG, will work to identify potential therapeutics based on that information. There is no cure for Parkinson’s, but some medications can improve symptoms. Under the agreement between the two companies, after the multi-year deal ends, 23andMe can conduct additional research on the data and make it available to other Parkinson’s researchers. The data will be contributed only by individuals who provide explicit permission to 23andMe.

The original press release can be read at: http://www.reuters.com/article/2015/01/06/23andme-roche-genome-idUSL1N0UL18L20150106

Disclaimer: This article does not reflect any personal views of the authors/editors

Previous articleBreakthrough: e-Dura, a flexible spinal implant could help paralyzed people walk again!
Next articleScientists identify a new target for the treatment of acute myeloid leukaemia (AML)
Scientist-entrepreneur-manager-journalist: -Co-founder, Author; Former Assistant Editor and Director, Biotechin.Asia, Biotech Media Pte. Ltd.; -Founder & CEO, SciGlo (www.sciglo.com); -Programme Management Officer, SBIC, A*STAR (former Research Fellow). --Sandhya graduated from University of Madras, India (B.Sc Microbiology and M.Sc Biotechnology) and received her Ph.D from the Nanyang Technological University, Singapore. She worked on oxidative stress in skin, skeletal, adipose tissue and cardiac muscle for a decade from 2006-2016. She is currently working as a Programme Management Officer handling projects and grants at Singapore Bioimaging Consortium (SBIC), Agency for Science, Technology and Research (A*STAR). Earlier to this she was a Research Fellow in the Fat Metabolism and Stem Cell Group at SBIC. Sandhya was also the Vice President and Publicity Chair of A*PECSS (A*STAR Post Doc Society) (2014-2016). Recently she founded a platform for scientists - SciGlo (www.sciglo.com) and is a startup mentor at Vertical VC (Finland). She is an ardent lover of science and enjoys globe trotting and good vegetarian food.